TrialThe Journal of dermatology2017

Secukinumab improves psoriasis symptoms in patients with inadequate response to cyclosporine A: A prospective study to evaluate direct switch.

Mamitaro Ohtsuki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.